8-K: Health In Tech Stockholders Approve Key Proposals

Sentiment:

Annual Meeting of Stockholders 12 November 2026 8:09 AM

Health In Tech, Inc. held its 2026 Annual Meeting of Stockholders, with overwhelming support for director elections, share authorization increases, and equity plan amendments.

Capital raiseApproval of issuances under the Standby Equity Purchase Agreement with YA II PN, Ltd., including upon conversion of convertible notes, indicates potential for capital raises.The increase in authorized shares from 220,000,000 to 720,000,000 provides significant capacity for future equity issuances.

Summary

Health In Tech, Inc. (HIT) held its 2026 Annual Meeting of Stockholders on November 10, 2026.
Stockholders overwhelmingly approved all five proposals presented.
Key approvals include the election of five directors, an increase in authorized shares, approval of issuances under a standby equity purchase agreement, an amendment to the equity incentive plan, and ratification of independent auditors.
A quorum was present, with approximately 90.53% of the outstanding voting power represented.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, indicating strong shareholder support for key corporate actions and governance.

Positives

All five director nominees were elected, ensuring continuity and new perspectives on the board.
Shareholders approved a significant increase in authorized capital stock from 220,000,000 to 720,000,000 shares.
Approval of issuances under the Standby Equity Purchase Agreement with YA II PN, Ltd. passed with strong support.
The Health In Tech, Inc. Equity Incentive Plan (2024) was amended to increase authorized shares for awards, indicating a commitment to employee and executive incentives.
MaloneBailey, LLP was ratified as the independent auditor for the fiscal year ending December 31, 2026.
High shareholder turnout (90.53% of voting power) demonstrates strong engagement.

Negatives

While not explicitly negative, the significant increase in authorized shares (from 220 million to 720 million) could lead to substantial dilution if fully utilized without corresponding value creation.

Risks

Potential for significant dilution of existing shareholders if the increased authorized shares are fully issued.
The company's reliance on equity issuances, as indicated by the approval of the Standby Equity Purchase Agreement, may suggest ongoing capital needs.

Future Outlook

The filing does not contain specific forward-looking financial guidance, but the approval of increased authorized shares and the equity incentive plan suggests a strategy for future growth and potential capital needs.

Management Comments

The company's Board of Directors approved a revision to Proposal Four to increase the total number of shares of Class A Common Stock authorized for issuance under the Health In Tech, Inc. Equity Incentive Plan (2024).

Industry Context

StockSavvy.ai notes that the approval of increased authorized shares and equity incentive plans is common for growth-oriented technology companies seeking to attract and retain talent and fund future expansion.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director	N/A	Tim Cortes	November 10, 2026	New director nominee elected by stockholders.
Director	Tim Johnson	Tim Johnson	November 10, 2026	Incumbent director re-elected by stockholders.
Director	Julia (LinLin) Qian	Julia (LinLin) Qian	November 10, 2026	Incumbent director re-elected by stockholders.
Director	William D. Howard	William D. Howard	November 10, 2026	Incumbent director re-elected by stockholders.
Director	Timothy Hayes	Timothy Hayes	November 10, 2026	Incumbent director re-elected by stockholders.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Amendment to Articles of Incorporation	Increase in total authorized shares of capital stock from 220,000,000 to 720,000,000.	November 10, 2026	Significantly increases the company's ability to issue stock for financing, acquisitions, or employee compensation, but also increases potential for dilution.
Amendment to Equity Incentive Plan	Increase in authorized Class A Common Stock for awards under the 2024 Equity Incentive Plan from 10,677,849 to 30,677,849 shares, and aggregate incentive stock option limit to 13,000,000 shares.	November 10, 2026	Enhances the company's ability to incentivize and retain employees and executives through stock-based compensation.

Stakeholder Impact

Shareholders: Potential for dilution due to increased authorized shares, but also potential for value creation if capital is used effectively. Re-election of directors ensures continuity.
Employees: Enhanced opportunities for stock-based compensation through the amended equity incentive plan.
Management: Increased flexibility in capital raising and employee incentives.

Next Steps

The elected directors will serve until the annual meeting of stockholders in 2027.
The company can now proceed with issuing shares under the amended equity incentive plan and the standby equity purchase agreement.
The company will continue its operations with MaloneBailey, LLP as its independent auditors for fiscal year 2026.

Key Dates

Date	Description
2026-09-18	Record date for determining stockholders entitled to vote at the Annual Meeting.
2026-10-13	Date of the Company's definitive proxy statement filed with the SEC.
2026-10-27	Date the Company's Board of Directors approved a revision to Proposal Four (2024 Plan Amendment Proposal).
2026-10-28	Date of the supplement to the Proxy Statement filed with the SEC.
2026-11-10	Date of the 2026 Annual Meeting of Stockholders.
2026-11-12	Date the report was signed.
2026-11-10	Date of earliest event reported.

Recommendation

hold

The filing indicates strong shareholder support for corporate actions that enable future growth and capital raising. However, the significant increase in authorized shares carries a risk of dilution. Without specific financial performance data or clear use-of-proceeds for the potential capital raises, a 'hold' recommendation is prudent, pending further clarity on the company's strategic execution and financial results.

Keywords

Annual Meeting, Stockholder Vote, Director Election, Authorized Shares, Equity Incentive Plan, Auditor Ratification, Capital Increase, Standby Equity Purchase Agreement

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.